Assessment of inflammatory markers in patients with ulcerative colitis treated with tofacitinib

Completed

• Conditions: ulcerative colitis; 10017969

• Registration Number: NL-OMON40572
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. patients (*18 years) with ulcerative colitis with an indication to start Tofacitinib within the OCTAVE induction study (METC2012_072) and responding to this therapy
2. patients (*18 years) with ulcerative colitis with an indication to start Tofacitinib within the Open Label study (METC_075), after having been defined as a non-responder within the participation in the OCTAVE Induction study (METC2012_072)

Exclusion Criteria

subjects without previous treatment for UC

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>inflammatory infiltrate, transcription of inflammatory genes, phosphorylation<br /><br>of Jak/Stat proteins.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>none</p><br>